Fundraising Fox
/Companies
Sign in

Nuevocor

Singapore, SG · Founded 2021 · 29 employees on LinkedIn · 6 known investors

Find your way into Nuevocor

Each arrow is one introduction. Sign up to fill in the first one.

536 people can intro you to Monica

Ask Silke R. Sperling to introduce you to Monica Shah

You →Silke · together at National Heart, Lung, and Blood Institute →Monica

Sign up to find every way you can get introduced to Nuevocor

  • Your email: who you already know at Nuevocor, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Nuevocor team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Nuevocor is a biotechnology company developing gene therapy treatments for cardiovascular and metabolic diseases. The company leverages innovative cell biology and gene therapy technologies to address genetic and acquired cardiac conditions.

BiotechDigital HealthHealthtechMedical Devices

Founders & leadership

Nuevocor was founded in 2021 by Brian Burke, Mark Kay, Colin Stewart, and Yann Chong Tan.

BBBrian Burke
Brian BurkeCo-Founder and Advisor
MK
Mark KayCo-Founder and Advisor
CS
Colin StewartCo-Founder and Advisor
YCYann Chong Tan
Yann Chong TanCo-Founder and Advisor
MSMonica Shah
Monica ShahChief Medical OfficerMonica Shah is a cardiologist with expertise in cell and gene therapy, cardiovascular disease, and clinical research. She serves as Chief Medical Officer at Nuevocor, a biotechnology company developing gene therapy treatments for cardiovascular and metabolic diseases.
AG
Al GianchettiChief Executive Officer

Investors · 6

Kurma Partners✓ confirmed by NuevocorParis · $162K – $10.8M

How we know: Kurma Partners's portfolio page · the company's own site · funding news · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Boehringer Ingelheim Venture Fund✓ confirmed by NuevocorIngelheim am Rhein · $16.2M

How we know: the company's own site · funding news · open dataset · 5k.vc investor directory · Not right? Tell us

ClavystBiolisted by ClavystBioSingapore

How we know: ClavystBio's portfolio page · funding news · Not right? Tell us

Highlight CapitalreportedNanjin

How we know: funding news · Not right? Tell us

SEEDS CapitalreportedSingapore · $250K – $12M

How we know: funding news · Not right? Tell us

Funding

SEC filings, press & company announcements

$45M disclosed across 1 of 2 rounds · 2025

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Nuevocor Closes US$45 Million Series B Financing for Clinical Development of Novel Mechanobiology-Centered Therapy for Cardiomyopathyprnewswire.com · May 2025

Frequently asked questions

What does Nuevocor do?
Nuevocor is a biotechnology company developing gene therapy treatments for cardiovascular and metabolic diseases. The company leverages innovative cell biology and gene therapy technologies to address genetic and acquired cardiac conditions.
Who founded Nuevocor?
Nuevocor was founded by Brian Burke, Mark Kay, Colin Stewart, Yann Chong Tan in 2021.
Who are Nuevocor's investors?
Nuevocor's investors include Angelini Ventures, Kurma Partners, Boehringer Ingelheim Venture Fund, ClavystBio, Highlight Capital, SEEDS Capital.
How much funding has Nuevocor raised?
Nuevocor has disclosed $45M raised across 1 of its 2 known rounds.
Where is Nuevocor headquartered?
Nuevocor is headquartered in Singapore, SG.